Medline Inc. (MDLN) Analyst Ratings & Price Targets

Medline Inc.

MDLN · Nasdaq

Analyst Consensus

Buy

0 analysts

$33

Current

$45

Low

$45

Average

$45

High

Average target implies +37.95% versus the current price.

Analyst Ratings Synthesis

The supplied consensus header reports Buy across zero analysts, but the detailed services show a strongly positive consensus: Public cites 24 analysts with a Buy rating, Investing.com reports 23 buys, five holds and no sells among 28 recommendations, and StockAnalysis reports a Buy average rating from 27 analysts. Published average targets cluster from $50.12 to $53.56, while Investing.com gives the clearest range at $45 to $60. The most bullish published view is the unnamed $60 high estimate; Baird is least bullish after cutting its target to $45 from $57. No revision is dated within the reported week. The substantive disagreement centers on FDA-warning risk and declining earnings versus valuation upside.

Rating Actions

1 firm captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
Baird	—	Unrated Lowered price target	$45from $57	+38.0%	Jun 3, 2026	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Symbol: MDLN
Type: Stock
Sector: Health Care
Industry: Surgical & Medical Instruments & Apparatus
Exchange: Nasdaq

Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Illinois, the company employs more than 45,000 people worldwide and operates in more than 100 countries. To learn more about how Medline makes healthcare run better, visit www.medline.com.

Key Issues

Bullish view

Analyst targets generally sit above the recent share price, with averages ranging from $50.12 to $53.56 and a high estimate of $60, implying that earnings power can support additional appreciation.

Bearish view

StockAnalysis reports earnings of $1.16 billion, down 3.42%, while the supplied evidence does not provide a catalyst for renewed profit growth, leaving the upside case dependent on assumptions rather than demonstrated acceleration.

Analyst Consensus

See all

Buy

0 analysts

$33

Current

$45

Low

$45

Average

$45

High

Average target implies +37.95% versus the current price.

Earnings History

BeatMissNo estimate

Medline Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Peers